LSMIPTrustNetwork
Now Printing
DGP Scientific, Inc.
-
Target MarketUSA
-
Business categoryPharmaceutical, Biopharmaceutical, Others
-
Business functionRegulatory > Regulatory affairs, Regulatory > New Drug Application, Business consulting > Import, export
-
AuthorDavid Parkes, Ph D.
-
Outline of business- Research Pharmacology Leader and Consultant in the fields of preclinical pharmacology (diabetes, obesity, liver and cardiovascular disease; Regulatory document preparation and review)
- Scientific strategy expert on drug development for metabolic diseases
- Medical and scientific education expert
- Biotechnology Professional with extensive drug development and preclinical pharmacology experience in the fields of diabetes, obesity, NASH and cardiovascular disease - led preclinical development of exenatide, a first-in-class treatment for Type 2 diabetes, now approved worldwide as Byetta and Bydureon
- Specialties: Diabetes, NASH and Obesity Drug Development, In Vivo Models, Regulatory Submissions (IND/NDA/CTD), Medical Affairs, Education and Document Planning, New Technology Evaluation, Scientific Communication, Life-Cycle Planning, Academic Outreach, Cross-functional Team Leadership.
Current representative relationships include:
- Prosciento - Preclinical Scientific Consultant
- Gilead - Senior Scientific Consultant
- Astra Zeneca - Senior Consultant
- Fractyl - Senior Consultant
- Prolynx - Senior Consultant
-
David Parkes, Ph D. -
Now printing
-
Now printing
| Attachment | ||
|---|---|---|
| Contact info |
|
|
|
|
|
|
|
|
| Note | ||